Alnylam Pharmaceuticals, Inc.
ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products includeā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$328.73
Price+4.00%
$12.64
1Y
Price
Market Cap
$43.597b
Large
Price/Earnings 3y Avg5y Avg
141.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+13.2%
EBITDA Margin+17.0%
Net Profit Margin+12.8%
Free Cash Flow Margin+13.2%
EBITDA Margin+17.0%
Net Profit Margin+12.8%
Free Cash Flow MarginRevenue
$3.714b
+65.2%
1y CAGR+54.8%
3y CAGR+46.8%
5y CAGREarnings
$313.747m
+212.8%
1y CAGR+103.6%
3y CAGR+69.5%
5y CAGREPS
$2.33
+203.7%
1y CAGR+101.3%
3y CAGR+68.7%
5y CAGRBook Value
$789.176m
$4.966b
Assets$4.177b
Liabilities$1.278b
DebtDebt to Assets
25.7%
2.7x
Debt to EBITDAFree Cash Flow
$465.383m
+1192.7%
1y CAGR+366.0%
3y CAGR+278.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company